• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.在子宫内膜样子宫内膜癌患者中,考虑选定风险因素对血清HE4和CA125水平的分析。
Contemp Oncol (Pozn). 2016;20(6):463-467. doi: 10.5114/wo.2016.65606. Epub 2017 Jan 12.
2
Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer.结合子宫内膜癌的分期、分级和组织学类型评估肿瘤标志物HE4和CA125的水平。
Prz Menopauzalny. 2016 Nov;15(3):133-137. doi: 10.5114/pm.2016.63059. Epub 2016 Nov 15.
3
Preoperative markers for the prediction of high-risk features in endometrial cancer.预测子宫内膜癌高危特征的术前标志物。
World J Clin Oncol. 2020 Jun 24;11(6):378-388. doi: 10.5306/wjco.v11.i6.378.
4
Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes.血清人附睾分泌蛋白4和糖类抗原125检测在不同病理亚型早期子宫内膜癌诊断中的价值
Onco Targets Ther. 2015 May 26;8:1239-43. doi: 10.2147/OTT.S81853. eCollection 2015.
5
The value of serum HE4 and CA125 levels for monitoring the recurrence and risk stratification of endometrial endometrioid carcinoma.血清HE4和CA125水平在监测子宫内膜样腺癌复发及风险分层中的价值。
Heliyon. 2023 Jul 8;9(7):e18016. doi: 10.1016/j.heliyon.2023.e18016. eCollection 2023 Jul.
6
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。
Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.
7
Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.血清 HE4、CA125、CA724 和 CA19-9 对子宫内膜癌患者的临床意义。
Technol Cancer Res Treat. 2017 Aug;16(4):435-439. doi: 10.1177/1533034616666644. Epub 2016 Aug 24.
8
HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients.在高危子宫内膜癌患者复发性疾病的检测中,人附睾蛋白4(HE4)优于癌抗原125(CA125)。
Tumour Biol. 2018 Feb;40(2):1010428318757103. doi: 10.1177/1010428318757103.
9
Serum HE4 as a prognostic marker in endometrial cancer--a population based study.血清 HE4 作为子宫内膜癌的预后标志物——一项基于人群的研究。
Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.
10
HE4 is an independent prognostic marker in endometrial cancer patients.HE4 是子宫内膜癌患者的独立预后标志物。
Gynecol Oncol. 2012 Aug;126(2):186-91. doi: 10.1016/j.ygyno.2012.04.022. Epub 2012 Apr 21.

引用本文的文献

1
Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.局部免疫与全身免疫在卵巢癌中的整合:免疫治疗的意义。
Front Immunol. 2022 Nov 10;13:1018256. doi: 10.3389/fimmu.2022.1018256. eCollection 2022.
2
HE4 as a Biomarker for Endometrial Cancer.人附睾蛋白4作为子宫内膜癌的生物标志物
Cancers (Basel). 2021 Sep 23;13(19):4764. doi: 10.3390/cancers13194764.
3
Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.上皮性卵巢癌患者卵巢恶性肿瘤风险的诊断措施比较:一项荟萃分析。
Sci Rep. 2021 Aug 27;11(1):17308. doi: 10.1038/s41598-021-96552-9.
4
HE4 overexpression decreases pancreatic cancer Capan-1 cell sensitivity to paclitaxel via cell cycle regulation.人附睾蛋白4(HE4)过表达通过细胞周期调控降低胰腺癌Capan-1细胞对紫杉醇的敏感性。
Cancer Cell Int. 2020 May 12;20:163. doi: 10.1186/s12935-020-01248-1. eCollection 2020.
5
Usefulness of HE4 protein in differentiation of pelvic masses in woman.HE4蛋白在女性盆腔肿块鉴别诊断中的应用价值。
Prz Menopauzalny. 2019 Apr;18(1):27-32. doi: 10.5114/pm.2019.84154. Epub 2019 Apr 9.
6
The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer.醛脱氢酶 1(ALDH1)与 CD44 的结合与子宫内膜癌不良预后相关。
PLoS One. 2018 Oct 29;13(10):e0206685. doi: 10.1371/journal.pone.0206685. eCollection 2018.

本文引用的文献

1
Expression of HE4 in Endometrial Cancer and Its Clinical Significance.HE4在子宫内膜癌中的表达及其临床意义
Biomed Res Int. 2015;2015:437468. doi: 10.1155/2015/437468. Epub 2015 Oct 11.
2
The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.人附睾蛋白4在子宫内膜癌复发中的作用:如何选择最佳随访方案。
Tumour Biol. 2016 Apr;37(4):4973-8. doi: 10.1007/s13277-015-4324-z. Epub 2015 Nov 3.
3
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。
Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.
4
Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.人附睾蛋白4在子宫内膜癌中的预后价值及其在手术分期中的应用
J Obstet Gynaecol Res. 2015 Oct;41(10):1644-52. doi: 10.1111/jog.12764. Epub 2015 Jul 30.
5
Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics - our experience.CA125、HE4、ROMA及逻辑回归模型在盆腔肿块诊断中的诊断价值——我们的经验
Ginekol Pol. 2015 Apr;86(4):256-61. doi: 10.17772/gp/2070.
6
Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes.血清人附睾分泌蛋白4和糖类抗原125检测在不同病理亚型早期子宫内膜癌诊断中的价值
Onco Targets Ther. 2015 May 26;8:1239-43. doi: 10.2147/OTT.S81853. eCollection 2015.
7
Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.遗传性非息肉病性结直肠癌(HNPCC)携带者家族中女性卵巢癌和子宫内膜癌的管理:文献综述及波兰HNPCC家族癌症风险评估结果
Hered Cancer Clin Pract. 2015 Jan 16;13(1):3. doi: 10.1186/s13053-015-0025-2. eCollection 2015.
8
Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.肿瘤标志物HE4作为子宫内膜癌预后因素的效用:一项单中心对照研究。
Tumour Biol. 2015 Jun;36(6):4151-6. doi: 10.1007/s13277-015-3049-3. Epub 2015 Jan 11.
9
Quantifying the expression of tumor marker genes in lung squamous cell cancer with RNA sequencing.采用 RNA 测序技术定量检测肺鳞癌肿瘤标志物基因的表达。
J Thorac Dis. 2014 Oct;6(10):1380-7. doi: 10.3978/j.issn.2072-1439.2014.08.27.
10
A comprehensive review on metabolic syndrome.关于代谢综合征的综合综述。
Cardiol Res Pract. 2014;2014:943162. doi: 10.1155/2014/943162. Epub 2014 Mar 11.

在子宫内膜样子宫内膜癌患者中,考虑选定风险因素对血清HE4和CA125水平的分析。

Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.

作者信息

Abdalla Nabil, Piorkowski Robert, Slomka Anna, Kania Malgorzata, Sawicki Wlodzimierz, Cendrowski Krzysztof

机构信息

Medical University of Warsaw, Warsaw, Poland.

出版信息

Contemp Oncol (Pozn). 2016;20(6):463-467. doi: 10.5114/wo.2016.65606. Epub 2017 Jan 12.

DOI:10.5114/wo.2016.65606
PMID:28239284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5320459/
Abstract

THE AIM OF THE STUDY

To assess the difference of serum level of HE4 and CA125 among patients with endometrioid endometrial cancer, considering the presence or absence of selected risk factors.

MATERIAL AND METHODS

A retrospective study of 46 patients, whose serum level of HE4 and CA125 level was documented, admitted to our Clinic because of endometrioid endometrial cancer. The statistical difference of both markers was analyzed considering certain risk factors.

RESULTS

In the examined group of patients there was no significant statistical difference of HE4 and CA125 levels among patients with and without the following risk factors: older age, menopausal status, overweight and obesity, hypertension, diabetes, early menarche, and family history of certain cancers. Similar results were obtained within the subgroup of patients with stage I endometrial cancer. Both HE4 and CA125 were significantly higher in premenopausal patients than in those after menopause in the more advanced stages of the disease. The same results were obtained within group of patients with advanced histological grading G2 and G3. In this group, higher levels of CA125 were observed among patients without hypertension. Among patients with histological grade G1 the serum level of HE4 was higher in the group of patients older than 60 years than it was in younger patients.

CONCLUSIONS

In the examined group of patients serum levels of tumour markers may not be affected by the selected risk factors. Higher HE4 and CA125 levels among premenopausal patients may be an alarming sign of advanced stages and classes of histological grading.

摘要

研究目的

考虑特定风险因素的存在与否,评估子宫内膜样子宫内膜癌患者血清HE4和CA125水平的差异。

材料与方法

对46例因子宫内膜样子宫内膜癌入住我院且血清HE4和CA125水平有记录的患者进行回顾性研究。考虑某些风险因素分析两种标志物的统计学差异。

结果

在被检查的患者组中,有或无以下风险因素的患者之间,HE4和CA125水平无显著统计学差异:年龄较大、绝经状态、超重和肥胖、高血压、糖尿病、初潮早以及某些癌症的家族史。在I期子宫内膜癌患者亚组中也得到了类似结果。在疾病较晚期,绝经前患者的HE4和CA125均显著高于绝经后患者。在组织学分级为G2和G3的晚期患者组中也得到了相同结果。在该组中,无高血压患者的CA125水平较高。在组织学分级为G1的患者中,60岁以上患者组的血清HE4水平高于年轻患者组。

结论

在被检查的患者组中,肿瘤标志物的血清水平可能不受所选风险因素的影响。绝经前患者中较高的HE4和CA125水平可能是疾病晚期和组织学分级较高的警示信号。